Citius Aims To Use Prior Experience With CTCL Drug To Its Commercial Advantage

Apr 06 2022

• By Alaric DeArment

Listen to this article

The company announced positive data for I/Ontak, a reformulated version of the cutaneous T-cell lymphoma drug Ontak and aims to submit for approval later in 2022.

Citius announced results of its Phase III trial of I/Ontak in cutaneous T-cell lymphoma • Source: Alamy

Citius Pharmaceuticals, Inc. is gearing up to reintroduce a drug for cutaneous T-cell lymphoma (CTCL) onto the market as it prepares to submit new Phase III data for I/Ontak (denileukin diftitox) to the US Food and Drug Administration. The company hopes to benefit from physicians’ prior experience and familiarity with an earlier version of the treatment.

I/Ontak is a recombinant fusion protein combining the interleukin-2 receptor binding domain with diphtheria toxin fragments. It’s a reformulated version...

More from Rare Diseases

India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2
Oct 14 2025
A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.
Merck’s Winrevair Approved For PAH In Europe As Initial US Launch Progresses
Aug 26 2024
• By Mandy Jackson
Merck & Co. won European Commission approval for Winrevair on top of other medicines for pulmonary arterial hypertension and expects an initial EU launch in Germany.
BioMarin Recruits Amgen R&D’s Friberg, Roche Dealmaker Sabry To Leadership Team
Aug 21 2024
• By Mandy Jackson
The company, in its new profitable era, is bringing in new leadership, with Amgen VP of medical affairs for rare diseases Greg Friberg and recently retired Roche Partnering head James Sabry.
Gene Therapy Patient Pipeline Builds, But Slowly, In Q2
Aug 14 2024
• By Jessica Merrill
Bluebird, Vertex and Sarepta are starting to see some commercial gene therapy traction and expect momentum to pick up in the second half, while hemophilia remains a challenging area.

More from Scrip

EHA: Lilly’s Jaypirca Posts First Phase III Triplet Win In CLL While BTK Degraders Advance
Jul 15 2026
Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.
EHA: Lilly’s Jaypirca Posts First Phase III Triplet Win In CLL While BTK Degraders Advance - Clone
Jun 18 2026
Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.
Finance Watch: Biopharma IPOs On The Upswing, Including Ex-US Offerings
Jun 17 2026
ghghghghghjhjhjhj